US pharma major Bristol-Myers Squibb (NYSE: BMY) has announced that its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) has failed to meet a primary endpoint in the CheckMate -915 Phase III melanoma trial.
This regimen was being compared to Opdivo alone in patients who have had a complete surgical removal of stage IIIb/c/d or stage IV melanoma, and failed to reach statistical significance in the co-primary endpoint of recurrence-free survival (RFS) in people whose tumors expressed PD-L1 levels of less than 1%.
The Data Monitoring Committee recommended that the study continue unchanged. The study remains double-blinded and will continue to assess the other co-primary endpoint of RFS in the all-comer population.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze